Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis [PDF]
Lenihan, Daniel J +2 more
core +1 more source
Transthyretin Amyloid Cardiomyopathy: The Plot Thickens as Novel Therapies Emerge. [PDF]
Dimza M, Vasilakis G, Grodin JL.
europepmc +1 more source
Detecting Polyneuropathy in Patients with Hereditary Transthyretin Amyloid Cardiomyopathy. [PDF]
Arivalagan P +7 more
europepmc +1 more source
Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy: A Marker of Disease Severity but Not an Independent Predictor of Mortality. [PDF]
Penate CM +9 more
europepmc +1 more source
Discontinuation of Tafamidis in Wild-Type Transthyretin Amyloid Cardiomyopathy Patients. [PDF]
Baba Y +5 more
europepmc +1 more source
The Weight of Comorbidities in the Specific Treatment of ATTR-Related Amyloid Cardiomyopathy. [PDF]
Cantone A, Dicorato MM, Porcari A.
europepmc +1 more source
Early Access to Tafamidis for Patients With Transthyretin Amyloid Cardiomyopathy. [PDF]
Crespo-Leiro MG +9 more
europepmc +1 more source
CMR and Amyloid Cardiomyopathy
Kwong, Raymond Y. +1 more
openaire +1 more source
Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy. [PDF]
Witteles RM +7 more
europepmc +1 more source
Monitoring Disease Progression in Transthyretin Amyloid Cardiomyopathy. [PDF]
Ioannou A.
europepmc +1 more source

